Skip to main content

Table 1 Patients’ characteristics with metastatic gastric cancer

From: A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients

 

BCc1 nanomedicine

(n = 33)

Placebo

(n = 30)

Age, years

 Mean (SD)

59.8 ± 13

61.2 ± 12.93

Weight

 Mean (SD)

61.68 ± 12.24

55.62 ± 12.82

Gender (n)

 Male–female

23–10

20–10

Metastatic site (n)

 Liver

17

11

 Multiple site

9

10

 Lung

2

3

 Peritoneal carcinomatosis

5

4

Stage 4 (n)

33

30

 Site of involvement (n)

  Cardia

7

10

  Antrum

6

5

  Fundus

3

3

  Greater curvature

3

4

  Lesser curvature

4

3

  Diffuse

4

5

Intervention + chemotherapy (n)

14

19

Intervention + chemotherapy + radiotherapy (n)

0

1